Mechanistic target of rapamycin kinase (mTOR) as part of Mechanistic target of rapamycin complex 1 (mTORC1) (mTORC1)

The Mechanistic target of rapamycin complex 1 (mTORC1) is a highly conserved multi-protein signaling hub that integrates diverse environmental signals, including nutrient availability, energy status, and growth factors, to coordinate cellular growth and metabolism (Saxton and Sabatini, 2017, NIH). At its core is the mTOR kinase, which functions as a serine/threonine protein kinase belonging to the PI3K-related kinase family (Zoncu et al., 2011, NIH). When activated, mTORC1 promotes anabolic processes such as protein, lipid, and nucleotide synthesis while simultaneously inhibiting catabolic pathways like autophagy (Laplante and Sabatini, 2012, Portland Press). This regulation is critical for maintaining cellular homeostasis and supporting the high metabolic demands of proliferating cells. Dysregulation of the mTORC1 pathway is frequently observed in human diseases, particularly in various cancers where hyperactivation drives uncontrolled cell growth and survival (Patsnap, 2024). It is also the primary driver of genetic syndromes such as Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) (Wikipedia). Therapeutic targeting of mTORC1 began with rapamycin and its analogs (rapalogs), which act as allosteric inhibitors by forming a complex with FKBP12 (Sabatini et al., 1994, NIH). More recently, second-generation ATP-competitive mTOR inhibitors have been developed to provide more comprehensive inhibition of the kinase activity, addressing the limitations of rapalogs in suppressing certain downstream substrates like 4E-BP1 (Zhang et al., 2019, NIH).

Other names

Mammalian target of rapamycin complex 1mTOR complex 1FRAP1RAFT1RAPT1

Allosteric inhibition via FKBP12 binding; ATP-competitive kinase inhibition